174775-41-8

Upstream product

• 6563-64-0 ethyl 5-nitrofuro[2,3-b]pyridine-2-carboxylate 
• 174775-40-7 t-Butyl 4-(5-cyanofuro[2,3-b]pyridine-2-carbonylamino)phenoxy-acetate 
• 6562-74-9 ethyl 5-aminofuro[2,3-b]pyridine-2-carboxylate 
• 174775-53-2 ethyl 5-cyanofuro[2,3-b]pyridine-2-carboxylate 
• 174775-52-1 5-cyanofuro[2,3-b]pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 2. Condensed heterocyclic derivatives

A novel series of platelet receptor glycoprotein (Gp) IIb/IIIa antagonists with condensed heterocycles as their basic core was synthesized. In an in vitro assay, trans-4-(5-amidinobenzofuran-2- carboxamido)cyclohexyl]oxyacetic acid 17e and trans-3-[4-(5-

CARBOXYLIC ACID COMPOUND HAVING CONDENSED RING, SALT THEREOF AND PHARMACEUTICAL USE THEREOF

A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases